期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

蛋白质糖化氧化修饰产物参与慢性肾脏病进展 被引量：3

原文传递
导出
摘要 慢性。肾脏病（CKD）是一组进行性的慢性疾病群,其最终后果是发展至终末期。肾病（ESRD）。ESRD患者虽能依赖肾替代治疗（透析或肾移植）生存,但耗费大量医疗资源。据统计,在美国CKD患者占医疗人群的6％,但其治疗费用却占医疗总预算的24％。我国40岁以上成人CKD的发生率约为10％,1999年中华医学会肾脏病学分会透析移植登记资料显示,每年至少新增2万名尿毒症患者（不包括尚未进入登记系统的城镇）。据估算,未来10年全世界用于尿毒症患者的医疗费用将超过1万亿美元。毋庸置疑,CKD已成为当前重要的“全球公众健康问题”。
作者 郭志坚 侯凡凡
机构地区 南方医科大学附属南方医院肾脏病研究所
出处 《中华内科杂志》 CAS CSCD 北大核心 2009年第6期510-512,共3页 Chinese Journal of Internal Medicine
基金 国家自然科学基金（30830056,30600289） 国家“973”项目（2006CB503904）
关键词 慢性肾脏病 修饰产物 糖化氧化 蛋白质 尿毒症患者 ESRD患者 医疗资源 肾替代治疗
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献31

  • 1Collins A J, Couser WG, Dirks JH, et al. World Kidney Day: an idea whose time has come. Kidney Int, 2006, 69:781-782.
  • 2Li ZY, Xu GB, Xia TA, et al. Prevalence of chronic kidney disease in a middle and old-aged population of Beijing. Clin Chim Acta, 2006, 366: 209-215.
  • 3Eddy AA, Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol, 1996, 7: 2495-2508.
  • 4Schieppati A, Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney Int, 2003, 64:1947-1955.
  • 5Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med, 2006,354 : 131-140.
  • 6Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol, 2007, 18 : 1889-1898.
  • 7Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-Ⅱ receptor blocker and angiotensin-convertingenzyme inhibitor in non-diabetic renal disease (COOPERATE) : a randomised controlled trial. Lancet, 2003, 361 : 117-124.
  • 8Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/ prorenin receptor in angiotensin Ⅱ production and cellular responses to renin. J Clin Invest, 2002, 109:1417-1427.
  • 9Miyata T, Kurokawa K. Carbonyl stress: increased carbonyl modification of proteins by autoxidation products of carbohydrates and lipids in uremia. Int J Artif Organs, 1999, 22:195-198.
  • 10Hou FF, Ren H, Owen WF Jr, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol, 2004, 15:1889-1896.

二级参考文献12

  • 1Foley RN, Parfrey PS, Sarnak MJ.Clinical epidemiology of cardiovascular disease in chronic renal disease.Am J Kidney Dis,1998,32(5 Suppl 3):S112-S119.
  • 2Witko-Sarsat V, Friedlander M, Capeillere-Blandin C,et al.Advanced oxidation protein products as a novel marker of oxidative stress in uremia.Kidney Int, 1996,49:1304-1313.
  • 3Witko-Sarsat V, Friedlander M, Nguyen Khoa T,et al.Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.J Immunol,1998,161:2524-2532.
  • 4Stein G, Busch M, Muller A, et al.Are advanced glycation end products cardiovascular risk factors in patients with CRF?Am J Kidney Dis,2003,41(3 Suppl 1):S52-S56.
  • 5Craven TE, Ryu JE, Espeland MA,et al.Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study.Circulation,1990,82:1230-1242.
  • 6Stenvinkel P, Heimburger O, Paultre F,et al.Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.Kidney Int,1999,55:1899-1911.
  • 7Kaneda H, Taguchi J, Ogasawara K, et al.Increased level of advanced oxidation protein products in patients with coronary artery disease.Atherosclerosis,2002,162:221-225.
  • 8Schomin M, EIcnhardt A, Rita E. The micro-inflammatory state of uremia. Blood Purif,2000,18:327-332.
  • 9Santoro A, Mancini E.Cardiac effects of chronic inflammation in dialysis patients.Nephrol Dial Transplant,2002,17 Suppl 8:10-15.
  • 10许竹梅.超声检测动脉粥样硬化的进展:颈动脉内膜中层厚度的意义[J].心血管病学进展,1998,19(6):354-357. 被引量：49

共引文献40

同被引文献41

  • 1Glassock RJ.Is the presence of microalbuminuria a relevant marker of kidney disease?[J].Curr Hypertens Rep,2010,12(5):364-368.
  • 2Haraldsson B,Nystrom J,Deen WM.Properties of the glomerular barrier and mechanisms of proteinuria[J].Physiol Rev,2008,88(2):451-487.
  • 3Russo LM,Sandoval RM,Campos SB,et al.Impaired tubular uptake explains albuminuria in early diabetic nephropathy[J].J Am Soc Nephrol,2009,20(3):489-494.
  • 4Peters T.All about albumin:biochemistry,genetics,and medical applications[M].San Diego,CA:Academic Press,1996:24.
  • 5Russo LM,Bakris GL,Comper WD.Renal handling of albumin:a critical review of basic concepts and perspective[J].Am J Kidney Dis,2002,39(5):899-919.
  • 6Futrakul N,Sridama V,Futrakul P.Microalbuminuria-a biomarker of renal microvascular disease[J].Ren Fail,2009,31(2):140-143.
  • 7Sacksh DB,Bruns DE,Goldstein DE,et al.Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J].Clin Chem,2002,48(3):436-472.
  • 8Eckardt KU,Berns JS,Rocco MV,et al.Definition and classification of CKD:the debate should be about patient prognosis--a position statement from KDOQI and KDIGO[J].Am J Kidney Dis,2009,53(6):915-920.
  • 9Hallan SI,Ritz E,Lydersen S,et al.Combining GFR and albuminuria to classify CKD improves prediction of ESRD[J].J Am Soc Nephrol,2009,20(5):1069-1077.
  • 10Brantsma AH,Bakker SJ,de Zeeuw D,et al.Urinary albumin excretion as a predictor of the development of hypertension in the general population[J].J Am Soc Nephrol,2006,17(2):331-335.

引证文献3

二级引证文献15

中华内科杂志
2009年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部